Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliglustat once-daily versus twice-daily dosing in clinically stable Gaucher disease type 1
2009-015811-42Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eliglustat in Gaucher disease type 1 (GD1) (2 arms), sponsored by Sanofi. Primary endpoint: Clinical stability through Week 52. Started Nov 2010; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2009-015811-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015811-42.